TwoToBiotech

Company Overview

Snapshot

Founded in January 2008 by Orly Devary and Tamara Sandler, TwoToBiotech operated with 1–10 employees. The company secured $500,000 in total capital across one funding round.

Business overview

TwoToBiotech is a Health Tech & Life Sciences company focused on developing novel human peptide hormones for therapeutic applications. The company's core technology centers on identifying and utilizing specific monoclonal antibodies against peptide hormones, with a primary focus on treating autoimmune diseases, particularly type 1 and type 2 diabetes. TwoToBiotech has also explored a novel human cardiac peptide for glucose metabolism regulation, serving the pharmaceutical and biotechnology sectors within the healthcare and life sciences markets.

Company Intelligence Q&A

What is TwoToBiotech's primary focus?

TwoToBiotech focuses on developing novel human peptide hormones to treat diabetes and autoimmune diseases, leveraging platform technology with specific monoclonal antibodies against identified peptides.

When was TwoToBiotech founded and by whom?

TwoToBiotech was founded in January 2008 by Orly Devary, who serves as Co-founder & CEO, and Tamara Sandler, Co-founder & Chief Scientist.

What was the company's operational status as of March 2022?

TwoToBiotech ceased to operate in March 2022, transitioning to a Non-Active status.

What is the total capital raised by TwoToBiotech?

TwoToBiotech raised a total of $500,000 across one funding round.

What is the status of TwoToBiotech's product development?

TwoToBiotech's product development is in the R&D stage, with in-vivo studies showing potential for its antibody in treating type 1 and type 2 diabetes, and initial tests on mice for APC1 in type 2 diabetes showing promise.